ReviewAnnals of gastroenterological surgery2019
Local radicality and survival outcome of pancreatic cancer surgery.
Review in Annals of gastroenterological surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 48 citations in OpenAlex.
- SGLT2 inhibition induces autophagic flux blockade and sensitizes pancreatic cancer to EGFR-targeted therapy.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- The European Multidisciplinary Evidence-Based Guideline on Pancreatic Cancer: Methodological Protocol.Clinical and public health guidelines · 2026Article
- Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis.Annals of surgical oncology · 2026Article
- The Role of the Mesopancreas in Pancreatic Neuroendocrine Neoplasms.Journal of clinical medicine · 2026Article
- A case of successfully completed robot-assisted distal pancreatectomy for pancreatic tail cancer in a patient with prior colostomy: case report.International cancer conference journal · 2025Article
- Is multidisciplinary treatment effective for invasive intraductal papillary mucinous carcinoma?Annals of gastroenterological surgery · 2024Article
- Safety and Feasibility of Neoadjuvant-Modified FOLFIRINOX in Elderly Patients with Pancreatic Cancer.Cancers · 2024Article
- Article
- Oligo-like liver metastasis: A novel prognostic indicator to improve survival in pancreatic cancer.Annals of gastroenterological surgery · 2024Article
- Cholangitis and Interruptions of Neoadjuvant Chemotherapy Associate with Reduced Overall and Progression-Free Survival in Pancreatic Cancer.Annals of surgical oncology · 2024Article
- Impact of Different Surgical Approaches on Morbidity and Mortality in Patients with Borderline Resectable Pancreatic Head Carcinoma.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2024Article
- Does an extensive diagnostic workup for upfront resectable pancreatic cancer result in a delay which affects survival? Results from an international multicentre study.Annals of hepato-biliary-pancreatic surgery · 2023Article
- Earlier Diagnosis of Pancreatic Cancer: Is It Possible?Cancers · 2023Review
- Perioperative oncolytic virotherapy to counteract surgery-induced immunosuppression and improve outcomes in pancreatic ductal adenocarcinoma.Frontiers in oncology · 2023Review
- Preclinical Evaluation of a Humanized, Near-Infrared Fluorescent Antibody for Fluorescence-Guided Surgery of MUC16-Expressing Pancreatic Cancer.Molecular pharmaceutics · 2022Article
- Prognostic Impact of Resection Margin Status on Distal Pancreatectomy for Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2022Review
- Intraoperative Positive Pancreatic Parenchymal Resection Margin: Is It a True Indication of Completion Total Pancreatectomy after Partial Pancreatectomy for Pancreatic Ductal Adenocarcinoma?Current oncology (Toronto, Ont.) · 2022Article
- Parachute technique for portal vein reconstruction during pancreaticoduodenectomy with portal vein resection in patients with pancreatic head cancer.Langenbeck's archives of surgery · 2022Article
- Resection of Recurrent Pancreatic Cancer: Who Can Benefit?Visceral medicine · 2022Review
- What do surgeons need to know about the mesopancreas.Langenbeck's archives of surgery · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer remains a therapeutic challenge. Surgical resection in combination with systemic chemotherapy is the only option promising long-term survival and potential cure. However, only about 20% of patients are diagnosed with tumors that are still in a resectable stage. Even after potentially curative resection and modern regimens for adjuvant chemotherapy, the majority of patients develop local and systemic recurrence resulting in median overall survival times of 28-54 months. The predominance of systemic recurrence and its impact on survival may lead to the assumption that surgical radicality and local control play only minor roles in the treatment of pancreatic cancer. This review provides an overview of the recent literature on surgical radicality and survival outcome in pancreatic cancer. The current evidence on the extent of lymphadenectomy, the prognostic impact of the extent of lymph node involvement, and the impact of the resection margin status on postresection survival are reviewed. Data from recent studies performed in the context of modern surgery and adjuvant therapy provide good evidence of a considerable impact of local radicality on survival after pancreatic cancer surgery. Surgical techniques that have been developed to refine oncological resections and to increase local control as well as resectability are highlighted. These techniques include artery-first approaches, level-3 dissection with removal of the periarterial nerve plexus, the triangle operation, and extended resections. Local radicality and quality of surgical resection remain among the most important parameters that determine the chances for survival in patients with non-metastatic pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.